Waterloo pharmacy charged with violating controlled-substance regulations
The Walgreens store at 3910 University Ave., Waterloo. (Photo via Google Earth)
Two Iowa-licensed pharmacies affiliated with the Walgreens and CVS chains are charged with violating state regulations.
The Walgreens store located at 3910 University Ave., Waterloo, is charged by the Iowa Board of Pharmacy with failing to maintain ultimate accountability of controlled substances and records; failing to ensure accountability of controlled substances; failing to create and maintain complete and accurate records as required by law; and committing acts that would render their Controlled Substances Act registration 'inconsistent with the public interest.'
The board has not publicly disclosed the alleged conduct that gave rise to the charges or indicated when it occurred.
A board hearing on the charges is scheduled for Sept. 24, 2025.
In an unrelated action, the board recently charged CVS/Caremark CarelonRx Mail operation, which is based in Pennsylvania but is a licensed pharmacy provider in Iowa, with multiple regulatory violations.
The board has charged the company with distributing a drug or device to a patient without a prescription; knowingly making misleading, deceptive, untrue, or fraudulent representations in the practice of pharmacy or engaging in unethical conduct; violating the pharmacy laws or rules of another, unspecified state; and having a license revoked or suspended by another entity for conduct that is roughly equal to the grounds for disciplinary action in Iowa.
A board hearing on the charges is scheduled for June 25, 2025.
The board has not publicly disclosed the alleged conduct that forms the basis of the charges. The charges may be tied to a recent decision by the Missouri Board of Pharmacy to place on probation for three years the license of CVS/Caremark CarelonRx Mail. That decision was based on a finding that the company's California license had been sanctioned due to allegations the company was dispensing controlled substances for no legitimate medical purpose.
In December 2024, the U.S. Department of Justice sued CVS and many of its subsidiaries, including Iowa CVS, alleging the company sought reimbursement from federal health care programs for illegal prescriptions. The case is still pending, although the company has denied any wrongdoing.
The government alleges that from October 2013 through 2024, CVS knowingly filled prescriptions for controlled substances that lacked a legitimate medical purpose. Among the unlawful prescriptions that CVS allegedly filled were prescriptions for dangerous and excessive quantities of opioids, early fills of opioids, and 'trinity' prescriptions, an especially dangerous and abused combination of drugs made up of an opioid, a benzodiazepine and a muscle relaxant.
According to the government, CVS ignored substantial evidence from multiple sources, including its own pharmacists, indicating its stores were dispensing unlawful prescriptions. The complaint alleges the violations resulted from corporate-mandated performance metrics and incentivized compensation for employees that prioritized corporate profits over patient safety.
'CVS' actions helped to fuel the opioid crisis,' the Department of Justice has alleged, adding that in 'some particularly tragic instances, patients died after overdosing on opioids shortly after filling unlawful prescriptions at CVS.'
CVS is the nation's largest pharmacy chain, with more than 9,000 pharmacies across the United States.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
8 hours ago
- Fast Company
Rite Aid store closures update: Latest list includes doomed locations in California, Washington, and Oregon
The list of Rite Aid store closures continues to grow. As the drugstore chain prepares to sell off its remaining assets in the wake of filing for bankruptcy for a second time, the total number of locations marked for closure in court documents as of this week is at least 497 nationwide. The chain will eventually sell or shutter all of its 1,277 pharmacies as it winds down operations. According to a court filing on Thursday, the latest list includes 25 additional locations in Ohio, California, Oregon, and Washington state. Bids on Rite Aid's remaining assets are due on June 18. Pharmacy assets already sold Rite Aid has already reached agreements to offload some of its assets—notably, its valuable prescription files—to CVS, the country's largest pharmacy chain; Walgreens; and the Albertsons and Kroger grocery chains. As Fast Company previously reported, CVS agreed to buy prescription files for 625 of those pharmacies and take over 64 brick-and-mortar Rite Aid locations in Idaho, Washington, Oregon, home to many of the latest closures. Rite Aid's mass closures present particular challenges for customers in rural areas who rely on the chain for their medications, sparking concerns about pharmacy deserts. The broader wind-down has left many remaining locations with empty shelves as products run out. Fast Company has reached out to Rite Aid for additional information about the timeline of the closures. Here's what to know. Which Rite Aid stores are among the latest closings? According to this week's filing, the following 25 locations are set to close and may already be in the process of doing so. CALIFORNIA 2505 Mt Vernon Avenue, Bakersfield, CA 93306 602 Williams Road, Salinas, CA 93905 4322 South Figueroa Street, Los Angeles, CA 90037 1560 Sycamore Avenue, Hercules, CA 94547 32121 Camino Capistrano, San Juan Capistrano, CA 92675 1501 West Main Street, El Centro, CA 92243 10823 Zelzah Avenue Bldg D, Granada Hills, CA 91344 19035 Bear Valley Road, Apple Valley, CA 92308 7025 El Camino Real, Atascadero, CA 93422 24330 El Toro Road, Laguna Woods, CA 92637 295 West Main Street, Woodland, CA 95695 1735 E Walnut Avenue, Visalia, CA 93292 300 North Canon Drive, Beverly Hills, CA 90210 OREGON 2021 NW 185th Avenue, Hillsboro, OR 97124 681 Lancaster Drive NE, Salem, OR 97301 1970 Echo Hollow Road, Eugene, OR 97402 1560 Coburg Road, Eugene, OR 97401 Ohio 1955 Cleveland Road, Wooster OH 44691 WASHINGTON 2131 SW 336th Street, Federal Way, WA 98023 10407 SE 256th Street, Kent, WA 98030 5700 100th Street SW Ste 100, Lakewood, WA 98499 3116 NE Sunset Boulevard, Renton, WA 98056 140th Avenue SE, Renton, WA 98058 196th Street SW, Lynnwood, WA 98036 2860 NW Bucklin Hill Road, Silverdale, WA 98383 Where can I find the full list of Rite Aid closures? Previous filings have revealed closures as noted below: May 5: 47 initial locations May 9: 68 additional locations May 16: 95 additional locations May 23: 151 additional locations May 30: 111 additional locations How did Rite Aid get here? Rite Aid's Chapter 11 bankruptcy filings come less than one year are a similar filing in 2023. Like many drugstore chains, including CVS and Walgreens, Rite Aid has struggled with online competition from Amazon and other retailers and decreased profits from prescription drugs due to lower reimbursement rates.
Yahoo
8 hours ago
- Yahoo
Brain-injured woman wandered from Iowa facility before being found at Nebraska truck stop
Community NeuroRehab at Glen Oaks is a five-bed residential care facility in Coralville, Iowa. (Photo via Google Earth) A female resident of a Coralville care facility wandered from the home earlier this year and was later found at a Nebraska truck stop 265 miles away. The incident occurred in January at Community NeuroRehab's Glen Oaks facility in Coralville, a state-licensed, five-bed residential care facility for people with mental or developmental disabilities. Newly disclosed state records show that a worker at the facility told state inspectors on May 14, 2025, that she was working the morning shift at 9:40 a.m. on Jan. 2, 2025, when she checked on a resident who was due for her medication. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX The resident, who had previously been diagnosed with a traumatic brain injury, dementia and psychological issues, was not in her room. The worker discovered a bent window screen underneath the bed, and in looking out the window she saw a footprint on top of an air-conditioning unit directly under the window. It was snowing at the time, and the temperature was around 22 degrees. The staff then launched a search for the woman in the community. Shortly after 5 p.m., the resident's mother called the facility to report that her daughter had been found, confused and frightened, 265 miles away at a truck stop in Gretna, Nebraska. According to state inspectors' reports, the woman had 'hitched a ride from a semi-driver who drove her to Nebraska.' In their written report, state inspectors said the woman had 'engaged in some type of sexual activity,' as determined by the medical provider she saw on Jan. 3, 2025, 'resulting in a very traumatic 24 hours.' A review of lab work revealed that testing for sexually transmitted infections was negative, the inspectors reported. A worker at the home allegedly told inspectors she had been trained to check and make sure each resident was present at the beginning of her shift but acknowledged she had not done so on Jan. 2, 2025. Inspectors concluded the resident had walked 2.3 miles through a mostly residential neighborhood to an interstate highway and then hitched a ride where she appeared to have been picked up by the driver of a semi-truck. The Iowa Department of Inspections, Appeals and Licensing recently fined Community NeuroRehab $3,000 for resident-safety violations related to the incident. SUPPORT: YOU MAKE OUR WORK POSSIBLE
Yahoo
11 hours ago
- Yahoo
Omada Health goes public at $23 per share, marking second major digital health IPO in 2025
Omada Health (OMDA) has become the second major digital health company to debut on the public markets this year, with an initial public offering valued at $1.1 billion. The company follows a successful launch of Hinge Health (HNGE) last month, which plays in one of the same markets as Omada: musculoskeletal health guidance. But Omada is better known as a clinical health guidance company for multiple chronic diseases, with an emphasis lately on weight loss management. Omada began trading at $23 per share on the Nasdaq on Friday. By midday, Omada stock traded as high as $28 per share, up 47% from the $19 per share the stock was initially priced at. Read more about Omada's opening stock moves and today's market action. The digital health platform has found its footing in the weight management space, though not by offering popular GLP-1 treatments. The company doesn't plan on doing so in the future either, CEO Sean Duffy told Yahoo Finance. Duffy said that's one reason why "the capital markets have, in many ways, asked us to come in" to the public markets. The company has differentiated itself and avoided the pitfalls of an ever-changing GLP-1 market, which was plagued early on by shortages and then disruption after the FDA removed GLP-1s from its shortage list, ending access to copycats of the popular drugs. Omada provides clinical guidance to patients once they leave their doctor's office. It's a concept that Duffy and his co-founders realized was needed more than a decade ago when the weight loss market and technology were very different. When asked if Duffy regretted not going public during the pandemic, when digital health was experiencing an investment boom, he said no and added that the company had only begun expanding beyond diabetes into other care areas, including weight loss. "When you're becoming a public company, you want to make sure to have your proof points out there," Duffy said. "In retrospect, it was a great decision." But Omada does have the pandemic to thank for its growth, as it put a spotlight on digital health services. The company has grown its user base through partnerships with large companies that offer the services to employees. In addition, Omada is partnered with pharmacy benefit managers, including CVS (CVS) and Cigna (CI) — the latter of which is also an early investor through its ventures arm. Omada began its journey by serving the needs of diabetics, including a partnership with Abbott (ABT) and users of its Freestyle Libre continuous glucose monitoring devices. It has since expanded to the GLP-1 market by providing the same guidance services, including meal kits and lifestyle change advice, to patients. Still, the company has yet to turn a profit in its 14-year existence. Duffy said the company's losses are decreasing over time, and revenue continues to grow year over year. "We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis," the company said in its S-1 filing. The company stated it incurred net losses of $67.5 million and $47.1 million in 2023 and 2024, respectively. In the first quarter ended March 31 of this year, Omada lost $9.4 million compared to a $19 million loss in the same period a year prior. "We incurred net losses of $67.5 million and $47.1 million for the years ended December 31, 2023 and 2024, respectively, and $19.0 million and $9.4 million for the three months ended March 31, 2024 and 2025, respectively." Duffy said he hopes new investors can help guide the company to become a leading platform addressing chronic disease. "It's just a neat moment in time, where the new shareholders that are coming in can help me, and help us, imagine a path ... to bend the curve of disease," he said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
